On 12 October 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Veyvondi. The marketing authorisation holder for this medicinal product is Baxalta Innovations GmbH.

The CHMP adopted an extension to include prophylaxis against haemorrhage in patients with von Willebrand disease (VWD)

Source:- European Medicines Agency

Note: This is not an original PR, this reference is taken based on European Medicines Agency website